Drug Profile
Oxipurinol - XORTX Therapeutics
Alternative Names: Oxypurinol - XORTX; XORLO; XRx 101; XRx-008Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator XORTX Pharma
- Developer XORTX Therapeutics
- Class Anti-ischaemics; Antigouts; Antivirals; Pyrazoles; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Autosomal dominant polycystic kidney disease
- Phase II Acute lung injury
Most Recent Events
- 19 Mar 2024 XORTX Therapeutics plans a registrational trial for Autosomal dominant polycystic kidney disease in USA (PO),
- 03 Jan 2024 XORTX Therapeutics files for patent protection for Oxipurinol
- 31 Aug 2023 XORTX Therapeutics anticpates a feedback and a decision from the EMA, regarding submission of an Orphan Drug Designation (ODD) application for oxipurinol for the treatment of Autosomal dominant polycystic kidney disease, by December 2023